Vermillion
Bio-Rad agreed to the payment when it bought Vermillion’s proteomics tools business in 2006 for $20 million in cash and a $3 million investment.
After Ciphergen unloaded its proteomics tools business in order to focus on diagnostics, the company changed its name to Vermillion.
[November 5, 2007] (GenomeWeb News) - The US Patent and Trademark Office has re-issued a patent covering SELDI mass spec-related technology to Vermillion, formerly called Ciphergen, that entitles the diagnostics developer to a $2 million payment from Bio-Rad Laboratories, Vermillion said today. The mass spectrometry patent, US No. 6,734,022, is related to a method and apparatus used for analyte desorption and ionization, and is assigned to Baylor College of Medicine, Vermillion said when the USPTO declared it would give the company a re-examination certificate for the technology.